AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 51 min read$COYA

Coya Therapeutics, Inc. issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase…

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Compa

Original reporting
SEC EDGAR 8-K
Published Oct 5, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$COYA
Bullish
high confidence
Mentioned
$COYA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COYABullishLow
01

Why it matters

Full enrollment moves the program into the double‑blind treatment phase, setting the stage for data readout in early 2027.

02

Market read

Trial enrollment is a material milestone for a small‑cap biotech, potentially influencing its valuation ahead of data release.

03

What to watch

The trial still faces a long timeline; cash runway and upcoming data releases could dominate price action.

Relevance 7/10Novelty 8/10Timing: today

Background

Coya Therapeutics is a clinical‑stage biotech developing low‑dose IL‑2 and CTLA‑4 Ig combination for ALS.

Company-level read

Ticker impact

$COYABullishHigh confidence
Context

Coya Therapeutics announced full enrollment of 120 patients in its Phase 2/3 ALS trial, a first‑time disclosure of trial progress.

Expected impact

likely modest upside as investors price in potential positive Phase 2/3 data

Evidence & confidence

First report of enrollment signals progress; biotech stocks often rally on trial milestones.

Market effects

Sector

May boost interest in ALS therapeutic pipeline and related biotech peers.

Regional

Limited to US biotech sector.

Global

Minor, confined to specialty pharma investors.

Counterpoint

What could challenge this read

If the trial fails to meet endpoints, the enrollment news could be a false positive and lead to a sell‑off.

Key entities

  • company
    Coya Therapeutics, Inc.

    Biotech firm conducting the ALSTARS ALS trial.

  • executive
    Arun Swaminathan, Ph.D.

    CEO of Coya Therapeutics, signatory of the 8‑K filing.

Read at source← All news

Related articles

OCT 6
$COYAHighAI 8/10

Coya Therapeutics stock reiterated at Buy by H.C. Wainwright on trial enrollment

H.C. Wainwright reiterated a Buy rating on Coya Therapeutics (COYA) with a $18.00 price target, citing full enrollment in its Phase 2/3 ALSTARS trial for ALS treatment. The stock trades at $4.85, suggesting over 270% upside. The trial aims to evaluate COYA 302's efficacy and safety, with top-line data expected in early Q2 2027. The company holds more cash than debt, providing financial flexibility.

investing.com1 min
OCT 5
$COYAMedAI 8/10

Coya Gains on Test News

Coya Therapeutics (COYA) announced full enrollment of 120 participants in its Phase 2/3 ALSTARS Trial for ALS treatment. Topline data is expected in early Q2 2027. CEO Arun Swaminathan highlighted the milestone and the potential insights from the trial.

baystreet.ca2 min
OCT 5
$COYALowAI 8/10

Coya completes enrollment in ALS trial, data due early Q2 2027

Coya Therapeutics (COYA) completed enrollment in its Phase 2/3 ALSTARS trial for ALS treatment COYA 302, with 120 participants. Topline data is expected in early Q2 2027. The trial is a randomized, placebo-controlled study with primary endpoints measuring disease severity. COYA 302 has FDA Fast Track designation. Coya partnered with Dr. Reddy’s for commercialization outside Japan, South America, and Mexico.

investing.com1 min
SEP 15
$COYALowAI 8/10

Coya Therapeutics, Inc. issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3…

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Company’s co

SEC EDGAR 8-K1 min